Bodoor Khaldon, Matalka Ismail, Hayajneh Rami, Haddad Yazan, Gharaibeh Waleed
Department of Biology, Faculty of Science and Arts, Jordan University of Science and Technology, Irbid, Jordan.
Asian Pac J Cancer Prev. 2012;13(7):3037-46. doi: 10.7314/apjcp.2012.13.7.3037.
The diffuse large B-cell lymphoma (DLBCL) encompasses two major groups of tumors with uneven survival outcomes--germinal center B-cell (GCB) and non-germinal center B-cell (non-GCB). In the present study, we investigated the expression of GCB markers (BCL-6 and CD10) and non-GCB markers (CD138 and MUM-1) in an effort to evaluate their prognostic value. Paraffin-embedded tumor biopsies of 46 Jordanian DLBCL patients were analyzed, retrospectively, by immunohistochemistry to investigate the expression of BCL-6, CD10, CD138 and MUM-1. In addition, survival curves were calculated with reference to marker expression, age, sex and nodal involvement. Positive expression of BCL-6, CD10, CD138 and MUM-1 was shown in 78%, 61%, 39% and 91% of the cases, respectively, that of BCL-6 being associated with better overall survival (p = 0.02), whereas positive CD138 was linked with poor overall survival (p = 0.01). The expression of CD10 and MUM-1 had no impact on the overall survival. Among the clinical characteristics studied, diagnosis at an early age, nodal involvement and maleness were associated with a higher overall survival for DLBCL patients. Our results underline the importance of BCL-6 as a marker of better prognosis and CD138 as a marker of poor prognosis for DLBCL patients.
弥漫性大B细胞淋巴瘤（DLBCL）包括两组生存结果不均的主要肿瘤——生发中心B细胞（GCB）和非生发中心B细胞（非GCB）。在本研究中，我们调查了GCB标志物（BCL-6和CD10）和非GCB标志物（CD138和MUM-1）的表达情况，以评估它们的预后价值。我们对46例约旦DLBCL患者的石蜡包埋肿瘤活检标本进行回顾性免疫组化分析，以研究BCL-6、CD10、CD138和MUM-1的表达情况。此外，还根据标志物表达、年龄、性别和淋巴结受累情况计算了生存曲线。BCL-6、CD10、CD138和MUM-1的阳性表达率分别为78%、61%、39%和91%，其中BCL-6的阳性表达与较好的总生存率相关（p = 0.02），而CD138阳性与较差的总生存率相关（p = 0.01）。CD10和MUM-1的表达对总生存率没有影响。在所研究的临床特征中，DLBCL患者在早年诊断、有淋巴结受累和男性与较高的总生存率相关。我们的结果强调了BCL-6作为DLBCL患者较好预后标志物和CD138作为较差预后标志物的重要性。
